- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the results from its second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two efficacy studies demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness. This Phase III study was conducted in real-world conditions on boats in the coastal waters of the United States (U.S.).
Vanda Pharmaceuticals Announces Positive Results From Second Phase III Study Of Tradipitant, Confirming Efficacy In Preventing Motion Sickness-Related Vomiting
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.